haematologica

Journal of the Ferrata Storti Foundation

Caffeine impairs red blood cell storage quality by dual inhibition of ADORA2b signaling and G6PD activity

by Monika Dzieciatkowska, Ariel Hay, Aaron Issaian, Gregory R. Keele, Shaun Bevers, Travis Nemkov, Julie A. Reisz, Mark Maslanka, Daniel Stephenson, Amy L. Moore, Xutao Deng, Mars Stone, Kirk C. Hansen, Steven Kleinman, Philip J. Norris, Michael P. Busch, Grier P. Page, Nareg Roubinian, Yang Xia, James C. Zimring and Angelo D'Alessandro

Caffeine impairs red blood cell storage quality by dual inhibition of ADORA2b signaling and G6PD activity

Monika Dzieciatkowska,[1,#] Ariel Hay,[2,#] Aaron Issaian,[1] Gregory R. Keele,[3] Shaun Bevers,[1] Travis Nemkov,[1,4] Julie A Reisz,[1] Mark Maslanka,[1] Daniel Stephenson,[1] Amy L Moore,[3] Xutao Deng,[5,6] Mars Stone,[5,6] Kirk C. Hansen,[1] Steve Kleinman,[7] Philip J Norris[5,6] Michael P. Busch,[5,6] Grier P Page,[3] Nareg Roubinian,[5,6,8] Yang Xia,[9] James C Zimring,[2] Angelo D'Alessandro,[1,4,*]

1) Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA;
2) University of Virginia, Charlottesville, VA, USA
3) RTI International, Research Triangle Park, NC, USA
4) Omix Technologies Inc, Aurora, CO, USA
5) Vitalant Research Institute, San Francisco CA, USA
6) Department of Laboratory Medicine, University of California San Francisco, CA, USA
7) University of British Columbia, Victoria, British Columbia, Canada.
8) Kaiser Permanente Northern California Division of Research, Oakland, CA, USA
9) Southern Medical University of Changsha, China

 # These authors contributed equally and share the first authorship

**<u>*Corresponding author:</u>*
Angelo D'Alessandro, PhD
Department of Biochemistry and Molecular Genetics
University of Colorado Anschutz Medical Campus
12801 East 17th Ave., Aurora, CO 80045
Phone # 303-724-0096
E-mail: angelo.dalessandro@cuanschutz.edu
www.dalessandrolab.com

Running title: *ADORA2b/G6PD inhibition by caffeine in stored RBCs*

Acknowledgments:

Abstract:

Caffeine is the most widely consumed psychoactive substance globally, yet its peripheral physiological effects remain incompletely understood. Leveraging comprehensive data from 13,091 blood donors in the REDS RBC-Omics study, we identify caffeine as a significant modulator of red blood cell (RBC) storage quality and transfusion outcomes. Elevated caffeine levels were reproducible across multiple donations from 643 recalled donors, selected based on their extremes in hemolytic propensity. Both in the screening and recalled cohorts, higher caffeine levels were associated with disrupted RBC metabolism, characterized by reduced glycolysis, depletion of adenylate pools or 2,3-bisphosphoglycerate, and increased markers of oxidative stress and osmotic fragility, including kynurenine accumulation. These observations were recapitulated in plasma and RBCs of eight volunteers upon consumption of a cup of coffee independently of brewing method (Chemex vs espresso). Clinically, elevated caffeine correlated with increased hemolysis and lower post-transfusion hemoglobin increments, especially pronounced in recipients transfused with RBCs from donors carrying common polymorphisms in the ADORA2b gene, a key regulator of RBC metabolism in hypoxia. These human findings were mechanistically validated using a murine model deficient in ADORA2b, which demonstrated impaired glycolytic flux, compromised antioxidant defenses – including caffeine-dependent direct inhibition of recombinantly-expressed glucose 6-phosphate dehydrogenase, and decreased transfusion efficacy (lower hemoglobin increments, higher bilirubin post-transfusion), effects further exacerbated by caffeine exposure during storage. Our study positions caffeine consumption as a modifiable factor in blood transfusion practice, advocating for precision strategies that integrate genetic and exposome factors, and identifies metabolic interventions to enhance blood quality and clinical outcomes.

Keywords: Purine metabolism, transfusion, hemolysis, precision transfusion medicine;

One sentence summary: Caffeine consumption and genetic variants in the ADORA2b receptor synergistically impair red blood cell metabolism and transfusion efficacy, revealing a modifiable exposome–gene interaction for precision transfusion medicine.

INTRODUCTION

Caffeine is one of the most widely consumed psychoactive compounds worldwide, primarily sourced from coffee, tea, energy drinks, and sodas (1). In the United States, over 67% of adults report daily coffee consumption, averaging more than 1.5 cups per day (~135 mg), with 36% of adults reporting an average daily consumption of 3-5 cups. Globally, coffee consumption exceeds 10 billion kilograms annually and continues to grow at an estimated 5% per year (2). An 8-ounce cup of brewed coffee (~240 ml) contains approximately 95 mg of caffeine, while a 12-ounce can of cola (~355 ml) contains around 35 mg, and a standard energy drink may contain up to 160 mg. These widespread dietary exposures make caffeine one of the most pervasive modulators of systemic and cellular physiology.

As a non-selective antagonist of adenosine receptors, caffeine – a purine alkaloid - exerts its primary effects through blockade of A1 and A2A receptors in the central nervous system, enhancing alertness and psychostimulation (3). However, peripheral adenosine receptors — notably the A2B subtype (ADORA2B) — are also affected. Mature red blood cells (RBCs), though anucleate, express functional ADORA2B (4), a G protein-coupled receptor that activates cAMP production and downstream kinases such as protein kinase A (PKA) and AMP-activated protein kinase (AMPK) (5). In hypoxic conditions, adenosine levels increase, activating ADORA2B to stimulate glycolysis and 2,3-bisphosphoglycerate (2,3-BPG) synthesis (4). This facilitates oxygen unloading at the tissue level (6) and supports redox balance by favoring fluxes through glycolysis at the expense of the pentose phosphate pathway (PPP) (4), thereby limiting NADPH generation and thus NADPH-dependent glutathione recycling.

The clinical relevance of these pathways becomes evident in the context of blood storage, when oxidant stress to RBCs is high (7). Transfusion of packed RBCs is the most common medical procedure after vaccination in the U.S., with over 12 million units transfused annually. RBCs are stored for up to 42 days at 1–6°C, during which they undergo progressive biochemical deterioration (7). This "storage lesion" includes depletion of ATP and 2,3-BPG, oxidative damage to proteins and lipids, vesiculation, and membrane loss (7). Importantly, the capacity of stored RBCs to regenerate 2,3-BPG and maintain ATP upon rewarming is tightly linked to their capacity to circulate in vivo after transfusion, a gold standard parameter that assesses the quality of transfused blood, also referred to as post-transfusion recovery (PTR) (8).

Stored RBCs progressively lose the capacity to activate the PPP (9), resulting in decreased NADPH production and loss of antioxidant buffering capacity. This makes RBCs vulnerable to oxidative hemolysis (10), particularly in recipients with inflammatory conditions. Accumulation of purine catabolites such as hypoxanthine, a marker of oxidant stress and ATP degradation, further correlates with reduced RBC lifespan after transfusion (8). Therefore, pathways that preserve purine homeostasis and redox balance are critical targets for improving stored RBC quality.

High-altitude physiology offers a natural model for understanding the role of purine metabolism in RBC energy and redox physiology (11). At elevations above 3,000 meters, plasma adenosine levels rise by up to 10-fold, activating ADORA2B in RBCs to increase 2,3-BPG and enhance tissue oxygen delivery (4). In humans and mice, this adaptation is blunted when adenosine is enzymatically degraded (12) or ADORA2B is genetically deleted. In murine models, genetic manipulation or pharmacological activation of AMPK regulates RBC integrity (13) and improves 2,3-BPG and ATP levels (14). These mechanisms are beneficial to acclimatization to high altitude, to the extent that proteasomal degradation of the adenosine equilibrative nucleoside transporter ENT1

favors faster acclimatization upon reascent (15). Caffeine, by antagonizing ADORA2B, has the potential to impair this protective signaling.

Additionally, caffeine has been reported to directly and competitively bind to G6PD—the rate-limiting enzyme of the PPP—inhibiting its activity and reducing NADPH production (16). Xu and colleagues report that, in vitro, caffeine - at concentrations as low as 50 μM (equivalent to 1–2 cups of coffee) - reduces G6PD activity by up to 40%. Thus, habitual caffeine consumption could plausibly affect the redox capacity and glycolytic balance of donor RBCs, particularly during storage.

Beyond biological (age, BMI, sex) or genetic factors (17), the quality of stored blood is impacted by the so-called exposome, i.e., donors' dietary, recreational, professional or medical exposures that are not grounds for blood donor deferral (18). Two otherwise healthy blood donors may produce RBC units of vastly different storage quality due to recent dietary intake, medications, or occupational exposures.

Encouraged by interesting preliminary data (19), here we investigated the impact of caffeine on RBC storage quality, here we stratified 13,000 donors enrolled in the Recipient Epidemiology and Donor Evaluation Study (REDS) RBC Omics, with detailed genomic, metabolomic, and storage phenotype data. Leveraging this resource, we conducted a two-part investigation to determine how caffeine and ADORA2B signaling interact to shape RBC storage outcomes, including in vitro and post-transfusion hemolysis.

Methods In the interest of space, extensive details for this section are provided in **Supplementary Materials.**

REDS RBC Omics: Index and Recalled donors: Metabolomics analyses were performed on day 42 packed RBCs from 13,091 "index" donors enrolled across four blood centers as part of the Recipient Epidemiology and Donor evaluation Study (REDS RBC Omics). Omics results were analyzed as a function of single nucleotide polymorphisms (SNPs) mapping on the region coding for ADORA2b, as extrapolated from genomics data on 879,000 single nucleotide polymorphisms (SNPs). Donors ranking in the 5th and 95th percentile for end-of-storage hemolysis (n=643) were invited to donate a second ("recalled") unit, which was tested at storage days 10, 23 and 42 (1,929 samples) for hemolytic parameters, high-throughput metabolomics (20-22), proteomics (23), lipidomics (24). Results were analyzed as a function of caffeine levels and ADORA2b SNPs.

Caffeine consumption in healthy volunteers To interrogate the metabolic effect of caffeine consumption we randomized eight volunteer to consume a coffee cup either brewed as Chemex or espresso (n=4 per group). The eight volunteers were routine coffee consumers, had abstained from coffee consumption for the 24h prior to the study, and voluntarily enrolled in this study under the protocol no. 24-0764, approved by the Colorado Medical Institutional Review Board (COMIRB). Blood samples were collected at baseline and after 45 min and 5h from consuming the beverage, and plasma and RBCs were separated via gentle centrifugation (10 min at 4⁰C at 2,000 g) prior to metabolomics analyses.

G6PD activity assay in presence of caffeine We recombinantly expressed and purified a human canonical G6PD or the deficient African variant (V68M; N126D – class III variant, 10-60% residual activity)(25) – most prevalent in the REDS RBC Omics cohort (~13% of donors of African descent and 2% of donors of Hispanic descent (26)). Activity assays were performed as described (16), in presence or absence of 50 μM caffeine (16).

Storage and Post-transfusion recovery (PTR) studies in ADORA2b mice

Mouse post-transfusion recovery (PTR) studies were performed as previously described (27). Storage of ADORA2b KO mice (n=3) for 7 or 12 days was followed by transfusion into Ubi-GFP mice, which were used as recipients to allow visualization of the test cells in the non-fluorescent gate. To control for differences in transfusion and phlebotomy, mCherry (red fluorescent-labeled) RBCs were used as a tracer RBC population (never stored). These RBCs were added to stored RBCs immediately prior to transfusion. PTR was calculated by dividing the post-transfusion by the pre-transfusion ratio (Test/Tracer), with the maximum value set as 1 (or 100% PTR). In follow up experiments, PTR studies were repeated after supplementation of caffeine (100 µM – no. C0750 Sigma Aldrich) to citrate-phosphate-dextrose-adenine CPDA1 standard storage solutions (27). This concentration is consistent with physiological plasma caffeine levels in high-consumption donors (low to high range: 20–100 µM (19)) and in vitro studies mimicking real-life exposures (range 50–100 µM (16)).

Determination of hemoglobin and bilirubin increment via the vein-to-vein database Association of ADORA2b alleles with hemoglobin increments was performed by interrogating the vein-to-vein database, as described in Roubinian et al.(28). Analyses were performed on the whole REDS population and further stratified for caffeine measurements, with a focus on the upper 50th percentile of caffeine measurements in REDS donors.

RESULTS

High levels of caffeine in donor red blood cells are reproducible across time

To assess the extent and physiological impact of caffeine exposure on stored red blood cell (RBC) quality, we first quantified caffeine levels in packed RBC units from 13,091 donors enrolled in the REDS RBC Omics study. Caffeine levels were either below detection threshold or negligible in ~5,000 donors, spanning a broad and continuous distribution (**Figure 1A**). In the full cohort, caffeine levels correlated to metabolic changes in metabolism, including a negative association with branched chain amino acids (Valine, Isoleucine, Threonine) and the related carnitine-conjugated ketoacid (AC 5-OH), with positive association with the bacterial metabolites 3-sulfocatechol and hippurate, kynurenine metabolites (8-methoxykynurenate), and lipid oxidation products (prostaglandin A2/B2 isomers, several acyl-carnitines (AC – **Figure 1B**).

For a subset of donors (extreme hemolyzers) enrolled both in the Index and Recalled phase of the REDS RBC Omics study (n=643), caffeine levels in packed RBCs were reproducible across multiple donations 6–12 months apart (**Figure 1C**). Stratification of donors based on high vs low caffeine levels (n=1,000 per group) revealed interesting demographic trends, with higher levels dosed in older individuals, females under 51, and donors with lower BMI, especially donors of Caucasian descent enrolled by the American Red Cross (**Figure 1D**). Similar trends were observed for the primary caffeine metabolite, paraxanthine (80% of caffeine is metabolized to paraxanthine), which was higher in older donors or younger females of Caucasian descent, showing a strong positive correlation (0.7 Spearman) and stable ratios across donor ages and sex (**Supplementary Figure 1A-C**). However, paraxanthine to caffeine ratios, a proxy for caffeine metabolism, were tendentially higher in younger donors, especially females of African American, Asian and Hispanic descent (**Supplementary Figure 1A-D**). Metabolite quantitative trait loci (mQTL) analysis identified a region on chromosome 19 coding for cytochrome p450 2A6 (CYP2A6)

associated with paraxanthine and paraxanthine/caffeine levels in the REDS Index cohort (**Supplementary Figure 2A-B**). Top SNPs included rs7251570, rs76112798 and rs11667314, which were most prevalent in donors of Asian or European descent and significantly influenced paraxanthine metabolism (**Supplementary Figure 2C-D**).). Similar findings were recapitulated for the second most abundant caffeine metabolite (12% of total), theobromine, also mapping on the CYP2A6 region (**Supplementary Figure 3A-B**).

Caffeine levels in REDS donors or coffee consumption in volunteers is associated with altered metabolism and increased hemolysis

Comparative metabolomics between donors with the highest and lowest RBC caffeine levels identified significant alterations in central metabolism, including reduced glycolytic intermediates, increased purine catabolites, and changes in amino acid and redox pathways (**Figure 1.E**).

To isolate the impact of caffeine on the circulating metabolome, we performed metabolomics analyses on plasma and RBCs from eight volunteers after consuming a cup of coffee (Chemex or espresso – **Supplementary Figure 4**). Results showed transient elevation of circulating caffeine within 45 min, and rapid metabolism by 300 min. Elevation in sulfocatechol and other bacterial metabolites was observed in plasma and RBCs, consistent with caffeine's impact on the gut microbiome. Caffeine consumption was associated with a drop in RBC 2,3-BPG and an increase in markers of membrane lipid oxidation and remodeling, including free fatty acids, (hydroxy)acyl-carnitines and lipid hydroperoxides (20:4 HPETE – **Supplementary Figure 4**). Elevation of plasma 2,3-BPG over time suggested release from RBCs, possibly via minor hemolysis.

In the Recalled cohort (n=643), for which samples were collected at storage days 10, 23, and 42, caffeine levels remained stable (**Figure 1E-inset**), indicating that associated metabolic changes were not due to caffeine degradation. High caffeine levels correlated with significantly lower ATP and pentose phosphate pathway intermediates, suggesting impaired energy/redox metabolism and increased hemolytic propensity. Indeed, higher spontaneous and osmotic hemolysis at day 42 were observed in the high caffeine group (p<0.01 and p<0.0001, respectively – **Figure 1F**).

RBCs with high caffeine show redox imbalance, poor metabolic fitness, and impaired post-transfusion efficacy

Metabolomics, proteomics, and lipidomics analyses of RBCs from Recalled donors (n=100) revealed subtle but consistent separation by caffeine levels in 3D uMAP projections (**Figure 2A–B**). High caffeine levels tracked with increased donor age and were enriched in women under 51 (**Figure 2C**). Longitudinal metabolomics revealed sustained increases in hypoxanthine and kynurenine (**Figure 2D–E**), markers of oxidative stress previously associated with poor PTR. Higher osmotic fragility was confirmed (**Figure 2F**). Hive plot correlation analyses revealed altered metabolic networks in high caffeine units, with weaker associations between ATP or 2,3-BPG and hemolysis (**Figure 2G**), metabolites previously linked to better PTR and oxygen off-loading (8, 29-32).

Transfusion data from the REDS vein-to-vein database (**Figure 2H**) showed significantly lower hemoglobin increments in recipients of high-caffeine RBC units, particularly among donors carrying the ADORA2B SNP AX-13163261 (**Figure 2I**). The ADORA2B SNP rs758857 was also associated with higher increases in bilirubin post-transfusion, a hemolysis marker, independent of donor age or pre-transfusion bilirubin levels (n=1,598 - **Figure 2J, Supplementary Figure 5**).

In vitro, 50 µM caffeine inhibited recombinant G6PD activity but did not further decrease the activity of the African variant (V68M; N126D), suggesting partial inhibition

may explain metabolic defects (**Figure 2K**). Integrative omics and genomic analyses highlighted differences in membrane stability and ADORA2B variant prevalence among the top 50 discriminants between high and low caffeine donors (**Figure 2L**).

ADORA2b genetic variants are prevalent and associate with increased RBC hemolysis

We analyzed 879,000 SNPs in the REDS cohort focusing on ADORA2B. Several variants were common, including AX-13163261 (46.9% heterozygous, 19.9% homozygous – **Figure 3A–B**). Variants rs758857 and AX-13163261 were strongly associated with osmotic (p<e-50) and oxidative hemolysis (p<e-9 -**Figure 3C**), though not storage hemolysis. These alleles were enriched in older donors (rs72821748), those with higher BMI (rs758857), and African Americans (**Figure 3D–F**, **Supplementary Figure 6**). Metabolomics linked these SNPs to altered redox metabolism and elevated caffeine levels (**Figure 3G–I**).

ADORA2b knockout impairs glycolysis and redox homeostasis in stored murine RBCs

To model mechanisms, we stored RBCs from WT and ADORA2B KO mice for 0, 7, or 12 days (equivalent to human 0, 21, 42 days – **Figure 4A-B**). Untargeted metabolomics showed separation by genotype and storage duration (**Figure 4C**). Combined with tracing data from 1,2,3-$^{13}C_3$-glucose experiments, our results confirmed impaired glycolytic flux in KO RBCs (**Figure 4D**), with reductions in intermediates of glycolysis, PPP, and glutathione metabolism (**Figure 4E**, **Figure 5**). KO RBCs had lower adenylate pools (calculated as ATP+0.5 ADP/(ATP+ADP+AMP)) and altered GSH/GSSG ratios, consistent with oxidative stress seen in high-caffeine RBCs.

Loss of ADORA2b alters redox-sensitive proteins and proteostasis in stored RBCs

We profiled the RBC proteome of WT and KO mice across storage (days 0, 7, 12 – **Figure 6A**). PCA and LDA confirmed genotype-dependent differences (**Figure 6B–C**). Time-series ANOVA identified changes in redox regulators (Psmd5, Ube2l3), glycolysis enzymes (Pkm), cytoskeletal proteins (Tubb4a, Dmtn, Flna), vesiculation markers (Cltc) and several immunoglobulin chains (Igh-1a, Igh-3, Ighg1, Ighkc, Ighm, V185, V192, V307, V358, V422 – **Figure 6D**). Though speculative at this stage, these observations are consistent with higher immunoglobulin deposition and likely faster removal from circulation or shorter circulatory lifespan of ADORA2b KO RBCs. Redox proteomics revealed increasing oxidation over time in KO RBCs (**Figure 6E**). Pathway analysis implicated dysregulated proteostasis and antioxidant defenses (**Figure 6F**).

ADORA2b deletion impairs PTR in stored RBCs, an effect exacerbated by caffeine

PTR studies in GFP+ recipient mice transfused with WT or KO RBCs stored 7 or 12 days showed reduced recovery in KO RBCs (**Figure 7A–B**). PTR positively correlated with ATP and glycolytic intermediates (**Figure 7C–D**). Storage with 100 µM caffeine further reduced PTR in KO but not WT RBCs (**Figure 7F**), demonstrating a gene–environment interaction. Clustering of top caffeine- and storage-sensitive metabolites emphasized disruptions in redox and nucleotide metabolism in KO RBCs (**Figure 7E**). A mechanistic model (Figure 7G) proposes that genetic ablation of ADORA2b skews red blood cell metabolism toward the pentose phosphate pathway (PPP) at the expense of glycolysis. In this context, caffeine—through its dual role as an ADORA2b antagonist and a direct inhibitor of G6PD, the rate-limiting enzyme of the PPP—emerges as a double-edged metabolic modulator. Its effects are particularly deleterious in ADORA2b-deficient RBCs,

where the simultaneous inhibition of glycolysis and PPP exacerbates storage lesions and impairs post-transfusion recovery.

Adenosine supplementation only partially restored metabolic defects in human stored RBCs

Given the role of adenosine signaling, we tested adenosine supplementation (1, 5, 10 μM) in stored human RBCs (**Supplementary Figure 7**). Adenosine increased intracellular levels early in storage but had modest metabolic impact. Lactate was reduced; ATP, ADP, and 2,3-BPG were higher in the first week. After three weeks, AMP, IMP, and inosine increased in supplemented units, consistent with adenosine catabolism and limited long-term efficacy (**Supplementary Figure 7D–E**).

DISCUSSION

In the present study we report that caffeine, a ubiquitous dietary component, is a previously underappreciated factor influencing the quality of stored RBCs. By leveraging a large-scale cohort of more than 13,000 blood donors from the REDS RBC-Omics study, we demonstrate that caffeine levels – detected in blood products at biologically relevant thresholds in the micromolar to hundreds of micromolar range (19) - correlate strongly with impaired RBC metabolic integrity and increased storage or osmotic hemolysis, translating into decreased transfusion efficacy. Stratification of donors by circulating caffeine levels revealed demographic patterns consistent with established population-level consumption trends. Epidemiological surveys in the United States and Europe report higher average caffeine intake among older adults, largely attributable to habitual coffee consumption, which increases with age and plateaus in the 60s (33). Although men typically consume slightly more caffeine overall, studies suggest that women—particularly those under 51—may exhibit higher circulating caffeine concentrations due to slower metabolism influenced by hormonal factors, including estrogen and oral contraceptive use (33). Our measurements of paraxanthine/caffeine ratios are consistent with this model. Caffeine levels also tend to be higher in individuals with lower BMI, likely reflecting a smaller volume of distribution and possibly differences in metabolic clearance. Ethnic variation in both consumption habits and metabolism contributes further: non-Hispanic White individuals report the highest coffee intake in national surveys, a pattern reflected in our cohort, while inter-individual variation in CYP1A2 genotype and expression may additionally shape plasma caffeine levels (34). Collectively, these findings support the interpretation that lifestyle, demographic, and pharmacogenetic factors converge to influence measurable caffeine exposure in blood donors.

While caffeine effects on the central nervous system, cardiovascular disease and cancer (35) are well documented, peripheral actions - especially on mature erythrocytes - have remained underexplored, with the exception of pilot retrospective studies linking caffeine levels to RBC metabolic phenotypes in 15 volunteers (19). Here, we show that elevated caffeine in RBC units is consistently associated with a metabolic phenotype indicative of compromised glycolytic activity, reduced ATP, total adenylate pools and 2,3-BPG, as well as with heightened oxidative stress, ferroptosis-like processes (36) and osmotic fragility markers, including oxidized glutathione (37), lipid peroxidation products (36) and hydroxyacyl-carnitines (38), hypoxanthine (8) and kynurenine (30). These findings were validated in volunteers within 45 min to 5h after consuming coffee, independently from brewing methods (espresso vs Chemex). These biochemical alterations culminate in increased spontaneous and stress-induced hemolysis during storage, consistent with the

increased susceptibility to extravascular hemolysis via splenic sequestration and erythrophagocytosis (39) of storage-damaged RBCs that become energetically effete (40) and accumulate oxidant damage, leading to elevated proteasomal degradation (41, 42). Clinically relevant, recipients of RBC units from donors with high caffeine consumption experienced significantly lower post-transfusion hemoglobin increments. Importantly, these effects were more pronounced in donors harboring specific polymorphisms in the ADORA2b gene, a receptor expressed on RBC membranes for which caffeine is a competitive antagonist, illustrating a critical gene-exposome interaction (18).

Observations in human RBCs are mechanistically supported by our parallel studies in a murine model deficient in ADORA2b (43). While adenosine signaling via ADORA2b signaling has been previously linked to acclimatization to high altitude hypoxia by favoring energy metabolism to boost oxygen off-loading (4), our findings here underscore the critical role of purinergic signaling in maintaining RBC metabolism during refrigerated storage. Inhibition or genetic deletion of ADORA2b disrupts this adaptive metabolic program, mirroring the dysregulation induced by caffeine exposure. Consistently, ADORA2b knockout mice displayed marked reductions in glycolytic flux, ATP levels, and glutathione recycling, closely phenocopying the metabolic phenotype of stored RBCs from high-caffeine human donors. The resulting decline in post-transfusion RBC viability in knockout mice was further exacerbated by caffeine supplementation during storage, demonstrating a synergistic metabolic vulnerability. This convergence of genetic and pharmacologic perturbations supports a model in which ADORA2b ablation shifts RBC metabolism toward the pentose phosphate pathway, while caffeine imposes a dual inhibitory effect—blocking both ADORA2b signaling and G6PD enzymatic activity—ultimately compounding the impairment of RBC energy and redox homeostasis.

Inhibition or genetic deletion of ADORA2b disrupts this adaptive metabolic program, mirroring the dysregulation induced by caffeine exposure. Consistently, ADORA2b knockout mice displayed marked reductions in glycolytic flux, ATP levels, and glutathione recycling, closely phenocopying the metabolic phenotype of stored RBCs from high-caffeine human donors. The resulting decline in post-transfusion RBC viability in knockout mice was further exacerbated by caffeine supplementation during storage, demonstrating a synergistic metabolic vulnerability. This convergence of genetic and pharmacologic perturbations supports a model in which ADORA2b ablation shifts RBC metabolism toward the pentose phosphate pathway, while caffeine imposes a dual inhibitory effect—blocking both ADORA2b signaling and G6PD enzymatic activity—ultimately compounding the impairment of RBC energy and redox homeostasis.

Notably, our results confirm and expand upon previous hypotheses implicating caffeine as a direct inhibitor of G6PD (16). It must be noted that similar findings were observed in our pilot study comparing 15 donors with the highest vs lowest levels of caffeine from a pilot REDS RBC omics study on a subset of the larger index and recalled donor populations (19). In that study, lower levels of PPP metabolites were interpreted with lower oxidant stress in stored RBCs from donors who were also heavy caffeine consumers. Here, our direct enzymatic assays reveal inhibitory effects of caffeine on canonical G6PD activity at physiologically relevant concentrations. However, the effect did not further compound with G6PD deficiency when testing in vitro the activity of the African variant upon incubation with caffeine, explaining the lack of observational evidence suggesting potential increases in susceptibility to hemolysis in individuals with G6PD deficiency who consume caffeinated beverages. Therefore, the adverse effects of caffeine observed in stored RBC units are potentially also direct, mediated both through disrupted purinergic signaling (ADORA2b)

and direct enzymatic inhibition (G6PD), in part mimicking the increased susceptibility to hemolysis and impaired post-transfusion survival of RBCs from G6PD deficient donors(26, 28, 37, 44). Altogether, our findings revise prior interpretations of caffeine's antioxidant effects in stored RBCs and exemplify the power of integrating large-scale human cohort analyses with targeted mechanistic studies in murine models to elucidate exposome-driven phenotypes.

The translational implications of our findings are significant. First, donor caffeine consumption - a common dietary exposure for up to 75% of Americans - emerges as a modifiable behavioral factor potentially influencing RBC storage quality and transfusion outcomes. Given caffeine's short biological half-life, transient dietary modifications around the time of blood donation might mitigate its negative impact, aligning with blood donation guidelines in several European countries where donors are advised to limit caffeine intake prior to donation. Conversely, in other regions, such as the United States or Italy, caffeine consumption before blood donation is not actively discouraged and may even be implicitly encouraged due to its known beneficial acute effects on blood pressure, potentially expediting the donation process and reducing vasovagal reactions. Indeed, moderate caffeine intake can transiently increase donor blood pressure and vascular tone, facilitating venous access and blood withdrawal efficiency. However, this advantage must be balanced against caffeine's mild diuretic properties, which may predispose donors to dehydration—an established risk-factor for adverse donation-related events and poorer blood flow during collection.

Beyond caffeine, our findings advocate for incorporating donor exposome data—dietary habits, medication usage—along with genetic markers into precision transfusion medicine strategies aimed at informing blood inventory management. For example, RBC units from high-caffeine-consuming donors or individuals with high-risk ADORA2b polymorphisms might be preferentially allocated to scenarios where slight variations in RBC quality are clinically less impactful. Conversely, units from donors with low caffeine exposure and favorable genetic profiles could be prioritized for high-risk transfusion recipients, such as neonates or patients with severe anemia.

Moreover, our mechanistic insights point to possible pharmacological interventions aimed at bolstering ADORA2b signaling or downstream metabolic pathways during RBC storage. Adenosine supplementation to standard storage additives transiently boosted energy metabolism, leading to early increases in intracellular adenosine and total adenylate pools, followed by elevation of purine deamination products inosine and IMP after storage week 3. Altogether, these results are consistent with adenosine uptake via ENT1, rather than activation of ADORA2b, followed by deamination of adenosine itself or its metabolite AMP into inosine and IMP by adenosine deaminase (29) or RBC-specific AMP deaminase 3 (14) Degradation of adenosine supplements in storage mediate would thus only favor transient stimulatory effects of ADORA2b, while the absence in stored RBC units of hepatic CYP2As that can degrade caffeine would not similarly constrain the antagonistic effects on the same receptors. In light of these results, alternative strategies to stimulate ADORA2b might include non-degradable adenosine analogs or allosteric modulators specifically enhancing glycolysis and redox balance, thereby improving stored RBC resilience and transfusion efficacy. Preliminary data from models utilizing AMPK activators (13) or hypoxic storage (27, 45) conditions provide proof-of-concept for these approaches, highlighting the feasibility of metabolic modulation as a storage enhancement strategy. Corollary to these considerations, cytochrome p450 reductases are NADPH dependent enzymes.(46) As such, direct G6PD inhibition by caffeine may constrain the pools of the very NADPH necessary for its direct

catabolism or that of its metabolites like paraxanthine. Indeed, our mQTL analysis here identified an association between donor genetics (CYP2A6 SNPs, especially in donors of Asian and European descent) and paraxanthine metabolism, consistent with the literature (47, 48).

Even though our integrative approach combining human donor data, murine genetic models, and in vitro enzymatic assays offers compelling mechanistic insight into caffeine's effects on red blood cells, several limitations warrant consideration. First, our human interventional study was conducted on a small cohort, which lacked caffeine-naïve individuals, limiting broader generalizability. Second, while our enzymatic assays suggest direct inhibition of G6PD by caffeine, these findings require further validation in vivo, particularly in G6PD-deficient individuals, where no exacerbated hemolytic phenotype was observed. Third, the REDS Omics donor samples used in this study were collected nearly a decade ago, and while storage protocols have remained largely unchanged, shifts in donor demographics or transfusion practices over time may influence broader applicability. Additionally, although our murine model supports the proposed gene–environment interaction between ADORA2b deficiency and caffeine exposure, differences in RBC physiology between species or across humans (e.g., CYP2As) may affect translation to human transfusion outcomes. Lastly, caffeine's rapid cell permeability is inferred from its physicochemical properties, but the precise mechanisms of entry into RBCs - whether exclusively passive or involving transporters such as ENT1 - remain to be elucidated. Future studies should aim to address these gaps, explore donor screening strategies, and assess whether real-time dietary exposures like caffeine can inform individualized transfusion protocols.

While our study benefits from robust epidemiological evidence combined with detailed mechanistic validation, we acknowledge certain limitations. The modest effect sizes observed in clinical transfusion outcomes raise questions about the absolute clinical relevance. Nevertheless, given the substantial global volume of transfusions, even small improvements in RBC quality can translate into meaningful clinical benefits at the population level. Additionally, our animal model, though highly informative, utilized defined genetic modifications; thus, translating these findings to routine clinical settings demands further validation.

Collectively, our study positions caffeine consumption as a significant, modifiable factor influencing RBC metabolic responses to oxidant stress, here in the form of a common iatrogenic intervention such as storage under blood bank conditions. Our data thus suggests that caffeine might sensitize RBCs to hemolysis by osmotic or oxidant insults, common stressors for example in response to moderate (49) or strenuous exercise (50). It also underscores the importance of the gene-exposome interface in determining transfusion outcomes, advocating for precision approaches in transfusion medicine. Future investigations should further explore dietary guidance for donors, pharmacological enhancements of RBC metabolic pathways, and more comprehensive integration of donor metadata into clinical transfusion practices.

REFERENCES

1. Temple JL, Bernard C, Lipshultz SE, Czachor JD, Westphal JA, Mestre MA. The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry. 2017;8:80.

2. Cappelletti S, Piacentino D, Sani G, Aromatario M. Caffeine: cognitive and physical performance enhancer or psychoactive drug? Curr Neuropharmacol. 2015;13(1):71-88.

3. Ribeiro JA, Sebastião AM. Caffeine and adenosine. J Alzheimers Dis. 2010;20(1):S3-15.

4. Liu H, Zhang Y, Wu H, et al. Beneficial Role of Erythrocyte Adenosine A2B Receptor-Mediated AMP-Activated Protein Kinase Activation in High-Altitude Hypoxia. Circulation. 2016;134(5):405-421.

5. Sun K, D'Alessandro A, Xia Y. Purinergic control of red blood cell metabolism: novel strategies to improve red cell storage quality. Blood Transfus. 2017;15(6):535-542.

6. Donovan K, Meli A, Cendali F, et al. Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter. Haematologica. 2022;107(1):298-302.

7. Yoshida T, Prudent M, D'Alessandro A. Red blood cell storage lesion: causes and potential clinical consequences. Blood Transfus. 2019;17(1):27-52.

8. Nemkov T, Stephenson D, Earley EJ, et al. Biological and genetic determinants of glycolysis: Phosphofructokinase isoforms boost energy status of stored red blood cells and transfusion outcomes. Cell Metab. 2024;36(9):1979-1997.

9. Rogers SC, Ge X, Brummet M, et al. Quantifying dynamic range in red blood cell energetics: Evidence of progressive energy failure during storage. Transfusion. 2021;61(5):1586-1599.

10. Kanias T, Lanteri MC, Page GP, et al. Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. Blood Adv. 2017;1(15):1132-1141.

11. D'Alessandro A, Nemkov T, Sun K, et al. AltitudeOmics: Red Blood Cell Metabolic Adaptation to High Altitude Hypoxia. J Proteome Res. 2016;15(10):3883-3895.

12. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011;17(1):79-86.

13. Foretz M, Guihard S, Leclerc J, et al. Maintenance of red blood cell integrity by AMP-activated protein kinase α1 catalytic subunit. FEBS Letters. 2010;584(16):3667-3671.

14. Chen C, Xie T, Zhang Y, et al. Erythrocyte ENT1-AMPD3 Axis is an Essential Purinergic Hypoxia Sensor and Energy Regulator Combating CKD in a Mouse Model. J Am Soc Nephrol. 2023;34(10):1647-1671.

15. Song A, Zhang Y, Han L, et al. Erythrocytes retain hypoxic adenosine response for faster acclimatization upon re-ascent. Nat Commun. 2017;8:14108.

16. Xu H, Hu L, Liu T, et al. Caffeine Targets G6PDH to Disrupt Redox Homeostasis and Inhibit Renal Cell Carcinoma Proliferation. Front Cell Dev Biol. 2020;8:556162.

17. D'Alessandro A. Red blood cell metabolism: a window on systems health towards clinical metabolomics. Curr Opin Hematol. 2025;32(3):111-119.

18. Nemkov T, Stefanoni D, Bordbar A, et al. Blood donor exposome and impact of common drugs on red blood cell metabolism. JCI Insight. 2021;6(3):e146175.

19. D'Alessandro A, Fu X, Reisz JA, et al. Stored RBC metabolism as a function of caffeine levels. Transfusion. 2020;60(6):1197-1211.

20. Nemkov T, Hansen KC, D'Alessandro A. A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways. Rapid Commun Mass Spectrom. 2017;31(8):663-673.

21. Nemkov T, Yoshida T, Nikulina M, D'Alessandro A. High-Throughput Metabolomics Platform for the Rapid Data-Driven Development of Novel Additive Solutions for Blood Storage. Front Physiol. 2022;13:833242.

22. Nemkov T, Reisz JA, Gehrke S, Hansen KC, D'Alessandro A. High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods. Methods Mol Biol. 2019;1978:13-26.

23. Thomas T, Stefanoni D, Dzieciatkowska M, et al. Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients. J Proteome Res. 2020;19(11):4455-4469.

24. Reisz JA, Zheng C, D'Alessandro A, Nemkov T. Untargeted and Semi-targeted Lipid Analysis of Biological Samples Using Mass Spectrometry-Based Metabolomics. Methods Mol Biol. 2019;1978:121-135.

25. Luzzatto L, Bancone G, Dugué PA, et al. New WHO classification of genetic variants causing G6PD deficiency. Bull World Health Organ. 2024;102(8):615-617.

26. Page GP, Kanias T, Guo YJ, et al. Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. J Clin Invest. 2021;131(13):e146077.

27. Hay A, Dziewulska K, Gamboni F, et al. Hypoxic storage of murine red blood cells improves energy metabolism and post-transfusion recoveries. Blood Transfus. 2023;21(1):50-61.

28. Roubinian NH, Reese SE, Qiao H, et al. Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight. 2022;7(1):e152598.

29. Nemkov T, Sun K, Reisz JA, et al. Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica. 2018;103(2):361-372.

30. Nemkov T, Stephenson D, Erickson C, et al. Regulation of kynurenine metabolism by blood donor genetics and biology impacts red cell hemolysis in vitro and in vivo. Blood. 2024;143(5):456-472.

31. Dumbill R, Rabcuka J, Fallon J, et al. Impaired O2 unloading from stored blood results in diffusion-limited O2 release at tissues: evidence from human kidneys. Blood. 2024;143(8):721-733.

32. D'Alessandro A, Earley EJ, Nemkov T, et al. Genetic polymorphisms and expression of Rhesus blood group RHCE are associated with 2,3-bisphosphoglycerate in humans at high altitude. Proc Natl Acad Sci 2024;121(1):e2315930120.

33. Mitchell DC, Knight CA, Hockenberry J, Teplansky R, Hartman TJ. Beverage caffeine intakes in the U.S. Food Chem Toxicol. 2014;63:136-142.

34. Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl). 2010;211(3):245-257.

35. Dam RMv, Hu FB, Willett WC. Coffee, Caffeine, and Health. N Engl J Med. 2020;383(4):369-378.

36. D'Alessandro A, Keele GR, Hay A, et al. Ferroptosis regulates hemolysis in stored murine and human red blood cells. Blood. 2025;145(7):765-783.

37. D'Alessandro A, Fu X, Kanias T, et al. Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity. Haematologica. 2021;106(5):1290-1302.

38. Nemkov T, Key A, Stephenson D, et al. Genetic regulation of carnitine metabolism controls lipid damage repair and aging RBC hemolysis in vivo and in vitro. Blood. 2024;143(24):2517-2533.

39. Roussel C, Morel A, Dussiot M, et al. Rapid clearance of storage-induced microerythrocytes alters transfusion recovery. Blood. 2021;137(17):2285-2298.

40. van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood. 2005;106(13):4034-4042.

41. Tzounakas VL, Dzieciatkowska M, Anastasiadi AT, et al. Red cell proteasome modulation by storage, redox metabolism and transfusion. Blood Transfus. 2022;20(1):27-39.

42. Peltier S, Marin M, Dzieciatkowska M, et al. Proteostasis and metabolic dysfunction characterize a subset of storage-induced senescent erythrocytes targeted for post-transfusion clearance. J Clin Invest. 2025;135(9):e183099.

43. Erblang M, Drogou C, Gomez-Merino D, et al. The Impact of Genetic Variations in ADORA2A in the Association between Caffeine Consumption and Sleep. Genes (Basel). 2019;10(12):1021.

44. Francis RO, D'Alessandro A, Eisenberger A, et al. Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion. J Clin Invest. 2020;130(5):2270-2285.

45. D'Alessandro A, Yoshida T, Nestheide S, et al. Hypoxic storage of red blood cells improves metabolism and post-transfusion recovery. Transfusion. 2020;60(4):786-798.

46. Riddick DS, Ding X, Wolf CR, et al. NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab Dispos. 2013;41(1):12-23.

47. Low JJ, Tan BJ, Yi LX, Zhou ZD, Tan EK. Genetic susceptibility to caffeine intake and metabolism: a systematic review. J Transl Med. 2024;22(1):961.

48. Cornelis MC, Kacprowski T, Menni C, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Human Molecular Genetics. 2016;25(24):5472-5482.
49. Nemkov T, Skinner SC, Nader E, et al. Acute Cycling Exercise Induces Changes in Red Blood Cell Deformability and Membrane Lipid Remodeling. Int J Mol Sci. 2021;22(2):896.
50. Nemkov T, Stauffer E, Cendali F, et al. Long-Distance Trail Running Induces Inflammatory-Associated Protein, Lipid, and Purine Oxidation in Red Blood Cells. bioRxiv. 2025, Apr 09. doi:10.1101/2025.04.09.648006. [Preprint, not peer-reviewed].

FIGURES

Fig. 1 – Caffeine, donor biology and red blood cell (RBC) hemolysis in 13,091 REDS RBC Omics donors. Caffeine distribution in 13,091 packed RBC units from donors enrolled in the REDS RBC Omics study (**A**). In **B**, metabolic correlates to caffeine levels in the same blood units. In **C**, caffeine levels were reproducible across multiple independent donations 6-12 months apart from 643 Index donors who were also enrolled in the Recalled phase of the study, owing to their extreme hemolytic propensity (<5th or >95th percentile). In **D**, stratification of REDS Index donors based on caffeine levels (top and bottom 1,000 donors by high or low caffeine levels) as a function of donor sex, age, body mass index (BMI), self-reported ethnicity and blood center in which the donors enrolled. In **E**, the volcano plot highlight the significant metabolic changes between caffeine low and high donors (n=1,000 per group – ATP is highlighted in the violin plot in the bottom right corner) in REDS Index donors at storage day 42. In the recalled donor cohort (n=643), caffeine levels did not change in packed RBCs when dosed at storage day 10, 23 and 42 (indent line plot). In **F**, blood units with high caffeine levels were associated with significantly higher storage ad osmotic hemolysis (** $p<0.01$; **** $p<0.0001$).
Abbreviations: AC: Acyl-carnitine; BMI: Body Mass Index; Sex F: female; M: Male; Blood Center: ITxM: The Institute for Transfusion Medicine, Pittsburgh (now part of Vitalant); BCW: Blood Center of Wisconsin; BSRI: Blood Systems Research Institute (now Vitalant); ARC: American Red Cross.

Fig. 2 – Higher caffeine levels are associated with elevated osmotic fragility of 643 recalled donors packed RBC and lower hemoglobin increments in transfusion recipients. The 3D uMAP in **A** shows substantial overlap between packed RBCs with high or low caffeine (n=100 per group – distributions in **B**) as a function of storage duration (z axis). Caffeine was higher in donors older than 30, while higher caffeine levels were observed in female donors below the age of 51 compared to males (**C**). In **D-E**, blood units with elevated caffeine show significantly higher levels of metabolic markers of poor post-transfusion recovery, hypoxanthine ($p<0.05$ at storage day 42) and kynurenine ($p<0.01$ through the whole storage period). Recalled donor blood units with high caffeine showed significantly higher levels of osmotic hemolysis (**F**). In **G**, hive plot summarizes changes in correlation networks of low and high caffeine blood units to hemolysis parameters (spontaneous storage hemolysis, or after osmotic or oxidant stress), and to functional metabolic parameters, including adenosine triphosphate (ATP) and 2,3-bisphosphoglycerate (2,3-BPG). Upon interrogation of the REDS vein-to-vein database (**H**), transfusion of packed RBCs with high caffeine (or from donors repeatedly identified as heavy caffeine consumers – highest quartile) results in lower hemoglobin increments after transfusion, especially when the donors are also carriers of one or two alternative alleles for the single nucleotide polymorphism (SNP) for the adenosine receptor ADORA2b AX-13163261 (**I**). Similarly, transfusion of units from donors carrying 1 or 2 alleles for the ADORA2b rs758857 SNP was associated with higher delta-bilirubin increments, independently of caffeine levels (**J**). In vitro incubation of recombinantly expressed canonical or African G6PD variant (V68M; N126D) with 50 µM caffeine inhibited canonical but not deficient G6PD activity (**K**). In **L**, heat map of the top 50 significant differences between high and low caffeine level blood units in REDS RBC omics Index donors identifies donor age, markers of osmotic fragility (kynurenine), markers of lipid peroxidation (hydroxyacyl-carnitines and prostaglandin F2α) and alternative alleles for ADORA2b SNP rs758857 as the most significant differences between the two groups (high and low caffeine – n=1,000).
Abbreviations: ADORA2b: adenosine receptor A2b; G6PD: glucose 6-phosphate dehydrogenase; Hgb: hemoglobin; OH-AcCa: Hydroxy-acyl-carnitines.

Fig. 3 – Prevalence of ADORA2b SNPs in REDS Index donors and association with hemolytic propensity. A list of the ADORA2b SNPs assayed in the 13,091 REDS Index donors is summarized in **A**, and the prevalence of heterozygosity or homozygosity for the alternative alleles is show in **B**. In **C**, SNP association to osmotic (blue), oxidative (red) or storage hemolysis (green). In **D-F**, stratification of the ADORA2b SNPs most strongly associated with hemolysis (especially osmotic and oxidative) by donor demographics (sex and ethnicity; age and demographics are shown in **Supplementary Figure 1**). In **G-I**, volcano plots of Spearman correlation of allele copies to metabolites and hemolysis parameters in the same SNPs.
Abbreviations: SNP: single nucleotide polymorphism; FA: fatty acid.

Fig. 4 – ADORA2b regulates glycolytic fluxes in stored RBCs. A literature-based summary model of the role of ADORA2b in regulating RBC metabolic fluxes through glycolysis based on Liu et al. Circulation 2016 (**A**). In **B**, packed RBCs from WT C57BL6/J mice (n=3) and ADORA2b KO mice (n=3) were stored for 0, 7, 12 days (equivalent to human RBC storage for 42 days) under refrigerated conditions in standard storage solutions, prior to metabolomics analysis. In **C**, principal component analysis of metabolomics data from this

study shows a significant effect of storage duration and genotype. In **D**, the experiment was repeated by supplementing CPDA1 with 5 mM 1,2,3-$^{13}C_3$-glucose, which affords the direct measurements of metabolic fluxes through glycolysis by measuring the $^{13}C_3$-lactate isotopologue. Results indicate a significant decrease in $^{13}C_3$-lactate in ADORA2b KO mice. In **E**, heat map of the top 50 metabolites by time series two-way ANOVA (by genotype and storage) in WT vs ADORA2b KO mice at storage day 0, 7 and 12.
Abbreviations: WT: wild-type; *ADORA2b: adenosine receptor A2b;* KO: knockout; FA: fatty acid; AC: acyl-carnitine; AMP: adenosine monophosphate. UHPLC-MS: ultra-high pressure liquid chromatography coupled to Mass Spectrometry.

Fig. 5 – Overview of glycolysis, the pentose phosphate pathway, glutathione and purine metabolism in stored WT and ADORA2b KO mice. Red lines: ADORA2b; Blue lines: WT; n=3 per group, median $\pm$ ranges (solid line and faded band) are shown for each metabolite.
*Abbreviations:* GLUC: glucose; HexP: hexose phosphate (glucose 6-phosphate and hexose phosphate isomers); FBP: fructose bisphosphate; G3P: glyceraldehyde 3-phosphate; PGLY: phosphoglycerate (2 and 3 isomers); PEP: phosphoenolpyruvate; PYR: pyruvate; LAC: lactate; PGLUC: 6-phosphogluconate; PentP: pentose phosphate (ribose 5-phosphate and pentose phosphate isomers); GSH: reduced glutathione; GSSG: oxidized glutathione; AXP: adenylate pool (ATP + 0.5 ADP / (ATP+ADP+AMP)).

Fig. 6 – Proteomics of stored RBCs from WT and ADORA2b knockout. In **A**, overview of the experimental design. Principal component analysis (**B**) and linear discriminant analysis (**C**) of proteomics results based on genotype and storage duration (0, 7 or 12 days). In **D**, heat map of the top 50 significant proteins (official gene symbols) by two-way time series ANOVA as a function of ADORA2b KO and storage duration. In **E**, top 25 sulfenic, sulfonic or cysteine to dehydroalanine redox modifications between WT and ADORA2b KO RBCs during storage. In **F**, pathway analysis based on proteomics results.
Abbreviations: protein names are abbreviated with official gene symbols.

Fig. 7 – ADORA2b KO negatively impacts post-transfusion recovery (PTR) of stored RBCs and is aggravated by caffeine supplementation. PTR studies were performed on stored (day 7 and 12) RBCs from WT and ADORA2b KO mice through transfusion into Ubi-GFP mice and co-transfusion with test mCherry fresh WT RBCs (**A**). Results indicate a significant drop in PTR in KO mice (**B**). In **C**, metabolic correlates to PTR. Supplementation of 100 μM caffeine to stored RBCs from WT and ADORA2b KO mice significantly impacted RBC metabolism (top 50 metabolites by two-way ANOVA are shown in the heat map in **D**). Highlights include cytidine monophosphate (CMP) and ATP (**E**). Caffeine supplementation further decreased PTR in ADORA2b KO mice (**F**). A working model is proposed in **G**, based on experimental data and existing literature on the role of caffeine as an ADORA2b antagonist and G6PD inhibitor.

A Caffeine distribution in 13k donors

B Caffeine correlates in 13K Donors

C Reproducibility of Caffeine levels across donations

Caffeine

Rho = 0.625
R² = 0.3209
p = 1.998 e-70

643 Donors
Measured twice

D Sex / Age / BMI / Ethnicity / Blood Center

E Caffeine – Volcano plot of metabolic differences between low and high caffeine consumers

F Hemolysis Storage (%) / Oxidative (%) / Osmotic (%)

A High vs Low Caffeine
(n=100 per group)

Storage (d)

uMAP1 uMAP2

B **Caffeine**
(normalized)

LOW

HIGH

C **Caffeine by Donor Age and Sex**

Donor age (y)

Sex
Female
Male

D *Markers of RBC storage quality*

Hypoxanthine

Caffeine
High
Low

E Kynurenine

Storage (day)

Caffeine
High
Low

F **Osmotic Hemolysis (%)**

Caffeine
High
Low

Storage (day)

G **Correlates to outcome**
based on Caffeine group

2,3-BPG
ATP
Caffeine
Oxidative Hemolysis
Osmotic Hemolysis
LOW
Storage Hemolysis

HIGH

|Spearman rho| > 0.65
Red >0.65
Blu < -0.65

H **Hemoglobin increments in single unit transfusion**
recipients in the Vein-to-Vein database (n = 1,598 events)

Storage

Donor Recipient

Vein-to-vein database

Post-transfusion delta Hgb

I **ΔHgb increment 24h after transfusion**
Caffeine upper quartile

g/dL

*** ****

ADORA2b AX-13163261 SNP alleles

J **ΔBilirubin increment**
immediately after transfusion

**** ****

ADORA2b rs758857 SNP alleles

K

NADPH (μM)

****
**
****
**
**
ns

G6PD canonical   G6PD A- (V68M N126D)
Caffeine - + - +

L

High caffeine (n=1000)   Low caffeine (n=1000)

Caffeine
PgF2α
Age
rs758857
ADORA2b

Top 50 by T-test

Kynurenine

OH-AcCa

20
0
-8

A ADORA2b SNP allele frequency in 13K REDS Index donors

Alleles	AX-13163261	rs758857	rs72821748	rs79990008	rs758856	rs17715109	rs73274391	rs2228101	rs116848446	rs75082014	rs115311614	rs73978562
0	33.2%	57.9%	86.3%	88.3%	93.8%	91.1%	98.1%	98.1%	97.4%	97.9%	99.6%	99.4%
1	46.9%	33.1%	13.2%	11.3%	5.9%	8.7%	1.9%	1.9%	2.6%	2.1%	0.4%	0.6%
2	19.9%	9.0%	0.5%	0.4%	0.3%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

B Allele Frequencies

C SNP Associations with Hemolysis

D rs758857 — Sex / Ethnicity

E rs72821748 — Sex / Ethnicity

F AX-13163261 — Sex / Ethnicity

G ADORA2b AX-13163261 SNP alleles associations in 13K REDS Index donors

H ADORA2b rs758857 SNP alleles associations in 13K REDS Index donors

I ADORA2b rs72821748 SNP alleles associations in 13K REDS Index donors

A Working model based on Liu et al. Circulation 2016

B

C Principal Component Analysis

D Glycolysis (Lactate +3)

E Hierarchical Clustering Analysis - Metabolomics

A n=3 WT, n=3 ADORA2b KO; Storage (day) 0, 7, 12; Proteomics

B Principal Component Analysis
- WT
- ADORA2b KO

C Linear Model: ADORA2b vs WT
Immunoglobulins
MUP18, VDAC3, TFRC, DAGLB

D Proteomics

Strain: WT, ADORA2b KO
Storage: 0, 7, 12

Col1a1, Pgam1, Serpina3m, Serpina1e, Serpina3k, Abce1, Hsph1, Rps27a, Eprs1, Arhgdia, Mup18, V905, Eif3l, Gstt1, Pklr, Actn4, Kng1, Tuba4a, Kpnb1, Ppp1cb, Dmtn, Cltc, V358, Ighm, Flna, Ighg1, Ube2l3, Plek, Psmd5, Pdia3, Tfrc, Vwf, Adipoq, Daglb, Hspa5, Glod4, Pkm, V307, V185, V192, Igh-1a, Igkc, Igh-3, V422, A1bg, Vdac3, Rpia, Pycard, Tubb4a, Tubb4b

E Proteomics (Cysteine Oxidation)

Strain: WT, ADORA2b KO
Storage: 0, 7, 12

Pafah1b1, Psma6, Ppm1b, Gpx1, Arhgdia, Cct7, Nap1l4, Alad, Fabp5, Igh-1a, V246, V166, V299, Psmb2, V162, Tubb1, Cd5l, A1bg, Tpt1, Flna, Sec14l2, Vwf, Ptpn11, F2, Ighv1, Stom, Igkc, Tubb4a, Pzp, Ighm, V272, Gapdh, Capg

F
Proteasome, Gap junction, Complement and Coagulation, Huntington disease, Neurotrophic signaling, Platelet activation, Salmonella infection, Parkinson disease, Prion disease, Spinocerebellar ataxia, Amyotrophic lateral sclerosis, Phospholipase D signalling, Alzheimer's disease, Neurodegeneration

Genes no.: 2, 3, 4, 5
-log10 (FDR): 1.5, 2.0, 2.5, 3.0
Fold enrichment: 0, 10, 20, 30, 40

A WT / ADORA2b KO; mCherry Fresh RBCs; Store for 7-12 days; Transfuse into Ubi-GFP mice

B Post-Transfusion Recovery %

C Correlates to Post-Transfusion Recovery

D Phenotype / Storage (day): ADORA2b KO, ADORA2b +Caf., WT, WT + Caffeine; 0, 7, 12

E CMP; ATP — ADORA2b, ADORA2b + caffeine, WT, WT + caffeine

F Post-Transfusion Recovery %

G Caffeine; Adenosine ◄ AMP ◄ ATP; ADORA2B; NADPH; G6PD; PPP; Glycolysis → ATP

SUPPLEMENTARY MATERIAL for

Caffeine impairs red blood cell storage quality by dual inhibition of ADORA2b signaling and G6PD activity

Monika Dzieciatkowska,[1,#] Ariel Hay,[2,#] Aaron Issaian,[1] Gregory R. Keele,[3] Shaun Bevers,[1] Travis Nemkov,[1,4] Julie A Reisz,[1] Mark Maslanka,[1] Daniel Stephenson,[1] Amy L Moore,[3] Xutao Deng,[5,6] Mars Stone, [5,6] Kirk C. Hansen,[1] Steve Kleinman,[7] Philip J Norris[5,6] Michael P. Busch,[5,6] Grier P Page,[3] Nareg Roubinian,[5,6,8] Yang Xia,[9] James C Zimring,[2] Angelo D'Alessandro,[1,4,*]

1)   Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA;
2)   University of Virginia, Charlottesville, VA, USA;
3)   RTI International, Research Triangle Park, NC, USA;
4)   Omix Technologies Inc, Aurora, CO, USA;
5)   Vitalant Research Institute, San Francisco CA, USA;
6)   Department of Laboratory Medicine, University of California San Francisco, CA, USA
7)   University of British Columbia, Victoria, British Columbia, Canada.
8)   Kaiser Permanente Northern California Division of Research, Oakland, CA
9)   Southern Medical University of Changsha, China

> # *These authors contributed equally and share the first authorship*

*Corresponding author:
Angelo D'Alessandro, PhD
Department of Biochemistry and Molecular Genetics
University of Colorado Anschutz Medical Campus
12801 East 17th Ave., Aurora, CO 80045
Phone # 303-724-0096
E-mail: angelo.dalessandro@cuanschutz.edu
www.dalessandrolab.com

Running title: *ADORA2b/G6PD inhibition by caffeine in stored RBCs*

TABLE OF CONTENTS

RESOURCE AVAILABILITY

Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Angelo D'Alessandro (angelo.dalessandro@cuanschutz.edu)

Materials availability ADORA2b KO mice have been previously described (1, 2), and are available upon reasonable request, finalization of material transfer agreement and after institutional ACUC approval through Dr James C Zimring Lab at the University of Virginia (jcz2k@virginia.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse RBC storage and post-transfusion recovery

Mouse post-transfusion recovery (PTR) studies were performed as previously described (3). Storage of conditional, erythroid-specific ADORA2b KO mice (n=3) for 7 days was followed by transfusion into Ubi-GFP mice, which were used as recipients to allow visualization of the test cells in the non-fluorescent gate. To control for differences in transfusion and phlebotomy, Ubi-mCherry RBCs were used as a tracer RBC population (never stored). These RBCs were added to stored RBCs immediately prior to transfusion. PTR was calculated by dividing the post-transfusion ratio (Test/Tracer) by the pre-transfusion ratio (Test/Tracer), with the maximum value set as 1 (or 100% PTR).

Donor recruitment in the REDS RBC Omics study:

Index donors A total of 13,758 donors were enrolled in the Recipient Epidemiology and Donor evaluation Study (REDS) RBC Omics at four different blood centers across the United States (https://biolincc.nhlbi.nih.gov/studies/reds_iii/). Of these, 97% (13,403) provided informed consent and 13,091 were available for metabolomics analyses in this study – henceforth referred to as "index donors". A subset of these donors were evaluable for hemolysis parameters, including spontaneous (n=12,753) and stress (oxidative and osmotic) hemolysis analysis (n=10,476 and 12,799, respectively) in ~42-day stored leukocyte-filtered packed RBCs derived from whole blood donations from this cohort (4). Methods for the determination of FDA-standard spontaneous (storage) hemolysis test, osmotic hemolysis (pink test) and oxidative hemolysis upon challenge with AAPH have been extensively described elsewhere (5).

Recalled donors: A total of 643 donors scoring in the 5th and 95th percentile for hemolysis parameters at the index phase of the study were invited to donate a second unit of pRBCs, a cohort henceforth referred to as "recalled donors". These units were assayed at storage days 10, 23 and 42 for hemolytic parameters and mass spectrometry-based high-throughput metabolomics (6), proteomics (7), lipidomics (8) and ICP-MS analyses (9). Under the aegis of the REDS-IV-P project (10), a total of 1,929 samples (n=643, storage day 10, 23 and 42) were processed with this multi-omics workflow.

METHOD DETAILS

High-throughput metabolomics Metabolomics extraction and analyses in 96 well-plate format were performed as described, with identical protocols for human or murine RBCs(11, 12). RBC samples were transferred on ice on 96 well plate and frozen at -80 ℃ at Vitalant San Francisco (human RBCs) or University of Virginia (murine RBCs) prior to shipment in dry ice to the University of Colorado Anschutz Medical Campus. Plates were thawed on ice then a 10 uL aliquot was transferred with a multi-channel pipettor to 96-well extraction plates. A volume of 90 uL of ice cold 5:3:2 MeOH:MeCN:water (*v/v/v*) was added to each well, with an electronically-assisted cycle of sample mixing repeated three times. Extracts were transferred to 0.2 µm filter plates (Biotage) and insoluble material was removed under positive pressure using nitrogen applied via a 96-well plate manifold. Filtered extracts were transferred to an ultra-high-pressure liquid chromatography (UHPLC-MS —

Vanquish) equipped with a plate charger. A blank containing a mix of standards detailed before (13) and a quality control sample (the same across all plates) were injected 2 or 5 times each per plate, respectively, and used to monitor instrument performance throughout the analysis. Metabolites were resolved on a Phenomenex Kinetex C18 column (2.1 x 30 mm, 1.7 um) at 45 °C using a 1-minute ballistic gradient method in positive and negative ion modes (separate runs) over the scan range 65-975 m/z exactly as previously described.(11) The UHPLC was coupled online to a Q Exactive mass spectrometer (Thermo Fisher). The Q Exactive MS was operated in negative ion mode, scanning in Full MS mode (2 µscans) from 90 to 900 m/z at 70,000 resolution, with 4 kV spray voltage, 45 sheath gas, 15 auxiliary gas. Following data acquisition, .raw files were converted to .mzXML using RawConverter then metabolites assigned and peaks integrated using ElMaven (Elucidata) in conjunction with an in-house standard library(14).

Lipid hydroperoxides and glutathionylated lipids: sample preparation: Oxylipins were extracted via a modified protein crash from previously described.[10,14,16] Extraction of oxylipins from red blood cells were as follows: 10 µL of red cells was aliquoted directly into 90 µL of MeOH:MeCN:H_2O (5:3:2, v:v:v) and pipetted up and down 5x per sample. Samples were then vortexed at 4 °C for 30 minutes. Following vortexing, samples were centrifuged at 12700 RPM for 10 minutes at 4 °C and 80 µL of supernatant was transferred to a new tube for analysis. 10 µL of extract from each sample was also combined to create a technical mixture, injected throughout the run for quality control. Lipidomics were extracted using identical prepartion techniques as oxylipins, save for utilizing MeOH:IPA (1:1, v:v) instead of MeOH:MeCN:H_2O (5:3:2, v:v:v) as an extraction buffer.

High-throughput Oxylipin Analysis: Analyses were performed as previously published via a modified gradient optimized for the high-throughput analysis of oxylipins.[10,14,16] Briefly, the analytical platform employs a Vanquish UHPLC system (Thermo Fisher Scientific, San Jose, CA, USA) coupled online to a Q Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). Lipid extracts were resolved over an ACQUITY UPLC BEH C18 column (2.1 x 100 mm, 1.7 µm particle size (Waters, MA, USA) using mobile phase (A) of 20:80:0.02 ACN:H_2O:FA and a mobile phase (B) 20:80:0.02 ACN:IPA:FA. For negative mode analysis the chromatographic the gradient was as follows: 0.35 mL/min flowrate for the entire run, 0% B at 0 min, 0% B at 0.5 min, 25%B at 1 min, 40%B at 2.5min, 55% B at 2.6min, 70% B at 4.5 min, 100% B at 4.6 min, 100% B at 6 min, 0% B at 6.1 min and 0% B at 7 min. The Q Exactive mass spectrometer (Thermo Fisher) was operated in negative ion mode, scanning in Full MS mode (2 µscans) from 150 to 1500 m/z at 70,000 resolution, with 4 kV spray voltage, 45 sheath gas, 15 auxiliary gas. Calibration was performed prior to analysis using the Pierce[TM] Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific).

High-throughput Lipidomic Analysis: Lipid extracts were analyzed (10 µL per injection) on a Thermo Vanquish UHPLC/Q Exactive MS system using a previously described(8) 5 min lipidomics gradient and a Kinetex C18 column (30 x 2.1 mm, 1.7 µm, Phenomenex) held at 50 °C. Mobile phase (A): 25:75 MeCN:H_2O with 5 mM ammonium acetate; Mobile phase (B): 90:10 IPA:MeCN with 5 mM ammonium acetate. The gradient and flow rate were as follows: 0.3 mL/min of 10% B at 0 min, 0.3 mL/min of 95% B at 3 min, 0.3 mL/min of 95% B at 4.2 min, 0.45 mL/min 10% B at 4.3 min, 0.4 mL/min of 10% B at 4.9 min, and 0.3 mL/min of 10% B at 5 min. Samples were run in positive and negative ion modes (both ESI, separate runs) at 125 to 1500 m/z and 70,000 resolution, 4 kV spray voltage, 45 sheath gas, 25 auxiliary gas. The MS was run in data-dependent acquisition mode (ddMS[2]) with top10 fragmentation. Raw MS data files were searched using LipidSearch v 5.0 (Thermo).

Mass spectrometry-based Proteomics analyses: Proteomics analyses were performed as described previously[78]. A volume of 10 µL of RBCs were lysed in 90 µL of distilled water containing 10 mM *N*-ethylmaleimide (NEM) for 20 min at room temperature. 5 µL of lysed RBCs were mixed with 45 µL of 5% SDS and then vortexed. Samples were reduced with 10 mM DTT at 55 °C for 30 min,

cooled to room temperature, and then alkylated with 25 mM iodoacetamide in the dark for 30 min. Next, a final concentration of 1.2% phosphoric acid and then six volumes of binding buffer (90% methanol; 100 mM triethylammonium bicarbonate, TEAB; pH 7.1) were added to each sample. After gentle mixing, the protein solution was loaded to a S-Trap 96-well plate, spun at 1500 x g for 2 min, and the flow-through collected and reloaded onto the 96-well plate. This step was repeated three times, and then the 96-well plate was washed with 200 μL of binding buffer 3 times. Finally, 1 μg of sequencing-grade trypsin (Promega) and 125 μL of digestion buffer (50 mM TEAB) were added onto the filter and digested carried out at 37 °C for 6 h. To elute peptides, three stepwise buffers were applied, with 100 μL of each with one more repeat, including 50 mM TEAB, 0.2% formic acid (FA), and 50% acetonitrile and 0.2% FA. The peptide solutions were pooled, lyophilized, and resuspended in 500 μL of 0.1 % FA. Each sample was loaded onto individual Evotips for desalting and then washed with 200 μL 0.1% FA followed by the addition of 100 μL storage solvent (0.1% FA) to keep the Evotips wet until analysis. The Evosep One system (Evosep, Odense, Denmark) was used to separate peptides on a Pepsep column, (150 um inter diameter, 15 cm) packed with ReproSil C18 1.9 µm, 120A resin. The system was coupled to a timsTOF Pro mass spectrometer (Bruker Daltonics, Bremen, Germany) via a nano-electrospray ion source (Captive Spray, Bruker Daltonics). The mass spectrometer was operated in PASEF mode. The ramp time was set to 100 ms and 10 PASEF MS/MS scans per topN acquisition cycle were acquired. MS and MS/MS spectra were recorded from m/z 100 to 1700. The ion mobility was scanned from 0.7 to 1.50 Vs/cm^2. Precursors for data-dependent acquisition were isolated within ± 1 Th and fragmented with an ion mobility-dependent collision energy, which was linearly increased from 20 to 59 eV in positive mode. Low-abundance precursor ions with an intensity above a threshold of 500 counts but below a target value of 20000 counts were repeatedly scheduled and otherwise dynamically excluded for 0.4 min.

Data analysis: Acquired data was converted from raw to mzXML file format using Mass Matrix (Cleveland, OH, USA). Analysis was done using MAVEN, an open-source software program for oxylipin analysis. Lipid assignments and peak integration were performed using LipidSearch v 5.0 (Thermo Fisher Scientific). Samples were analyzed in randomized order with a technical mixture injected interspersed throughout the run to qualify instrument performance.

Determination of hemoglobin and bilirubin increment via the vein-to-vein database Association of ADORA2b SNPs – as a function of caffeine levels - with hemoglobin increments was performed by interrogating the vein-to-vein database, as described in Roubinian et al. (15, 16)

Vein-to-vein database: General Study Design We conducted a retrospective cohort study using electronic health records from the National Heart Lung and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) program available as public use data through BioLINCC (17, 18). The database includes blood donor, component manufacturing, and patient data collected at 12 academic and community hospitals from four geographically diverse regions in the United States (Connecticut, Pennsylvania, Wisconsin, and California) for the 4-year period from January 1, 2013 to December 31, 2016. Genotype and metabolomic data from the subset of blood donors who participated in the REDS-III RBC-Omics study (19) was linked to the dataset using unique donor identifiers.

Study Population and Definitions Available donor genetic polymorphisms for ADORA2b were linked to issued RBC units using random donor identification numbers. Among transfusion recipients, we included all adult patients who received a single RBC unit during one or more

transfusion episodes between January 1, 2013 and December 30, 2016. Recipient details included pRBC storage age, and blood product issue date and time. We collected hemoglobin levels measured by the corresponding clinical laboratory prior to and following each RBC transfusion event (0h and 24h after transfusion).

Transfusion Exposures and Outcome Measures All single RBC unit transfusion episodes linked to genetic polymorphism for ADORA2b were included in this analysis. A RBC unit transfusion episode was defined as any single RBC transfusion from a single donor with both informative pre- and post-transfusion laboratory measures and without any other RBC units transfused in the following 24-hour time period. The outcome measures of interest were change in hemoglobin (ΔHb; g/dL) following a single RBC unit transfusion episode. These outcomes were defined as the difference between the post-transfusion and pre-transfusion levels. Pre-transfusion thresholds for these measures were chosen to limit patient confounding (e.g., underlying hepatic disease). For pre-transfusion hemoglobin, the value used was the most proximal hemoglobin measurements prior to RBC transfusion, but at most 24 hours prior to transfusion. Furthermore, we excluded transfusion episodes where the pre-transfusion hemoglobin was greater than 9.5 g/dL, and the hemoglobin increment may be confounded by hemorrhage events. For post-transfusion hemoglobin, the laboratory measure nearest to 24-hours post-transfusion, but between 12- and 36-hours following transfusion was used.

Storage of human packed RBCs in presence of adenosine

Leukocyte filtered packed RBCs (n=3 in experiment 1 and n=5 in experiment 2) were stored in standard CP2D-AS-3 (additive solution 3), either untreated or supplemented with 1, 5 or 10 μM adenosine (no. A9251- Sigma Aldrich; experiment 1) or 10 μM (experiment 2), a concentration below 14 μM – which would potentially be arrhythmia-inducing in transfusion recipients via stimulation of adenosine 1 receptor in cardiac atria (20).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical Methods We assessed the univariable association of all *a priori* selected donor, manufacturing, and recipient covariates with the outcomes using linear regression. Multivariable linear regression assessed associations between alleles of donor single nucleotide polymorphisms and changes in hemoglobin levels post-transfusion hemoglobin. Two-sided p-values less than 0.05 were considered to be statistically significant. Analyses were performed using Stata Version 14.1, StataCorp, College Station, TX.

Data analysis Statistical analyses – including hierarchical clustering analysis (HCA), linear discriminant analysis (LDA), uniform Manifold Approximation and Projection (uMAP), correlation analyses and Lasso regression were performed using both MetaboAnalyst 5.0 (21) and in-house developed code in RStudio (2024.12.1 Build 563).

REDS RBC Omics mQTL analyses of paraxanthine: The workflow for the mQTL analysis of paraxanthine and theobromine levels in REDS Index donors is consistent with previously described methods from our pilot mQTL study on 250 recalled donors (22). Details of the genotyping and imputation of the RBC Omics study participants have been previously described by Page, et al. (23) Briefly, genotyping was performed using a Transfusion Medicine microarray (24) consisting of 879,000 single nucleotide polymorphisms (SNPs); the data are available in dbGAP accession number phs001955.v1.p1. Imputation was performed using 811,782 SNPs that passed quality control. After phasing using Shape-IT (25), imputation was performed using Impute2 (26) with the 1000 Genomes Project phase 3 (26) all-ancestry reference haplotypes. We used the R package SNPRelate (27) to calculate principal components (PCs) of ancestry. We performed association analyses for paraxanthine using an additive SNP model in the R package ProbABEL (28) and 13,091 REDS Index

donor study participants who had both paraxanthine and theobromine levels measured. We adjusted for sex, age (continuous), frequency of blood donation in the last two years (continuous), blood donor center, and ten ancestry PCs. Statistical significance was determined using a p-value threshold of 5×10^{-8}. We only considered variants with a minimum minor allele frequency of 1% and a minimum imputation quality score of 0.80. The OASIS: Omics Analysis, Search & Information a TOPMED funded resources (29), was used to annotate the top SNPs. OASIS annotation includes information on position, chromosome, allele frequencies, closest gene, type of variant, position relative to closest gene model, if predicted to functionally consequential, tissues specific gene expression, and other information.

SUPPLEMENTARY REFERENCES

1. Qiang Q, Manalo JM, Sun H, Zhang Y, Song A, Wen AQ, Wen YE, Chen C, Liu H, Cui Y, Nemkov T, Reisz JA, Edwards Iii G, Perreira FA, Kellems RE, Soto C, D'Alessandro A, Xia Y. Erythrocyte adenosine A2B receptor prevents cognitive and auditory dysfunction by promoting hypoxic and metabolic reprogramming. PLoS Biol. 2021 Jun;19(6):e3001239. eng. The authors have declared that no competing interests exist. Epub 20210617. doi:10.1371/journal.pbio.3001239. Cited in: Pubmed; PMID 34138843.

2. Liu H, Zhang Y, Wu H, D'Alessandro A, Yegutkin GG, Song A, Sun K, Li J, Cheng NY, Huang A, Edward Wen Y, Weng TT, Luo F, Nemkov T, Sun H, Kellems RE, Karmouty-Quintana H, Hansen KC, Zhao B, Subudhi AW, Jameson-Van Houten S, Julian CG, Lovering AT, Eltzschig HK, Blackburn MR, Roach RC, Xia Y. Beneficial Role of Erythrocyte Adenosine A2B Receptor-Mediated AMP-Activated Protein Kinase Activation in High-Altitude Hypoxia. Circulation. 2016 Aug 2;134(5):405-21. Epub 2016/08/03. doi:10.1161/CIRCULATIONAHA.116.021311. Cited in: Pubmed; PMID 27482003.

3. Hay A, Dziewulska K, Gamboni F, Nerguizian D, Dzieciatkowska M, Zimring JC, D'Alessandro A. Hypoxic storage of murine red blood cells improves energy metabolism and post-transfusion recoveries. Blood Transfus. 2022 Oct 21. eng. Epub 2022/11/09. doi:10.2450/2022.0172-22. Cited in: Pubmed; PMID 36346885.

4. D'Alessandro A, Culp-Hill R, Reisz JA, Anderson M, Fu X, Nemkov T, Gehrke S, Zheng C, Kanias T, Guo Y, Page G, Gladwin MT, Kleinman S, Lanteri M, Stone M, Busch M, Zimring JC. Heterogeneity of blood processing and storage additives in different centers impacts stored red blood cell metabolism as much as storage time: lessons from REDS-III-Omics. Transfusion. 2019 Jan;59(1):89-100. eng. Disclosure of Conflict of interest ADA is a consultant for Hemanext Inc. TN and, ADA are founders of Omix Technologies Inc. JCZ serves on the scientific advisory board for Rubius Therapeutics. All the other authors disclose no conflicts of interest. Epub 20181024. doi:10.1111/trf.14979. Cited in: Pubmed; PMID 30353560.

5. Kanias T, Lanteri MC, Page GP, Guo Y, Endres SM, Stone M, Keating S, Mast AE, Cable RG, Triulzi DJ, Kiss JE, Murphy EL, Kleinman S, Busch MP, Gladwin MT. Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. Blood Adv. 2017 Jun 27;1(15):1132-1141. eng. Conflict-of-interest disclosure: D.J.T. served as a consultant to Fresenius Kabi. A.E.M. received research funding from Novo Nordisk and has received honoraria from Siemens. The remaining authors declare no competing financial interests. doi:10.1182/bloodadvances.2017004820. Cited in: Pubmed; PMID 29034365.

6. Nemkov T, Yoshida T, Nikulina M, D'Alessandro A. High-Throughput Metabolomics Platform for the Rapid Data-Driven Development of Novel Additive Solutions for Blood Storage [Original Research]. Frontiers in Physiology. 2022 2022-March-14;13. English. doi:10.3389/fphys.2022.833242.

7. Thomas T, Stefanoni D, Dzieciatkowska M, Issaian A, Nemkov T, Hill RC, Francis RO, Hudson KE, Buehler PW, Zimring JC, Hod EA, Hansen KC, Spitalnik SL, D'Alessandro A. Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients. medRxiv. 2020 Jun 30. Epub 2020/07/09. doi:10.1101/2020.06.29.20142703. Cited in: Pubmed; PMID 32637980.

8. Reisz JA, Zheng C, D'Alessandro A, Nemkov T. Untargeted and Semi-targeted Lipid Analysis of Biological Samples Using Mass Spectrometry-Based Metabolomics. Methods Mol Biol. 2019;1978:121-135. Epub 2019/05/24. doi:10.1007/978-1-4939-9236-2_8. Cited in: Pubmed; PMID 31119660.

9. Stephenson D, Nemkov T, Qadri SM, Sheffield WP, D'Alessandro A. Inductively-Coupled Plasma Mass Spectrometry-Novel Insights From an Old Technology Into Stressed Red Blood Cell Physiology. Front Physiol. 2022;13:828087. eng. Epub 2022/02/25. doi:10.3389/fphys.2022.828087. Cited in: Pubmed; PMID 35197866.

10. Josephson CD, Glynn S, Mathew S, Birch R, Bakkour S, Baumann Kreuziger L, Busch MP, Chapman K, Dinardo C, Hendrickson J, Hod EA, Kelly S, Luban N, Mast A, Norris P, Custer B, Sabino E, Sachais B, Spencer BR, Stone M, Kleinman S. The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion. 2022 May;62(5):982-999. eng. Epub 2022/04/21. doi:10.1111/trf.16869. Cited in: Pubmed; PMID 35441384.

11. Nemkov T, Yoshida T, Nikulina M, D'Alessandro A. High-Throughput Metabolomics Platform for the Rapid Data-Driven Development of Novel Additive Solutions for Blood Storage. Front Physiol. 2022;13:833242. eng. Epub 2022/04/02. doi:10.3389/fphys.2022.833242. Cited in: Pubmed; PMID 35360223.

12. Nemkov T, Reisz JA, Gehrke S, Hansen KC, D'Alessandro A. High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods. Methods Mol Biol. 2019;1978:13-26. Epub 2019/05/24. doi:10.1007/978-1-4939-9236-2_2. Cited in: Pubmed; PMID 31119654.

13. Stefanoni D, Shin HKH, Baek JH, Champagne DP, Nemkov T, Thomas T, Francis RO, Zimring JC, Yoshida T, Reisz JA, Spitalnik SL, Buehler PW, D'Alessandro A. Red blood cell metabolism in Rhesus macaques and humans: comparative biology of blood storage. Haematologica. 2020 Aug;105(8):2174-2186. Epub 2019/11/09. doi:10.3324/haematol.2019.229930. Cited in: Pubmed; PMID 31699790.

14. Nemkov T, Hansen KC, D'Alessandro A. A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways. Rapid Commun Mass Spectrom. 2017 Apr 30;31(8):663-673. Epub 2017/02/15. doi:10.1002/rcm.7834. Cited in: Pubmed; PMID 28195377.

15. Roubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, Hendrickson JE, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA. Donor

genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight. 2022 Jan 11;7(1). eng. Epub 2021/11/19. doi:10.1172/jci.insight.152598. Cited in: Pubmed; PMID 34793330.

16. Roubinian NH, Plimier C, Woo JP, Lee C, Bruhn R, Liu VX, Escobar GJ, Kleinman SH, Triulzi DJ, Murphy EL, Busch MP. Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion. Blood. 2019 Sep 26;134(13):1003-1013. eng. Epub 2019/07/28. doi:10.1182/blood.2019000773. Cited in: Pubmed; PMID 31350268.

17. https://biolincc.nhlbi.nih.gov/studies/reds_iii/.

18. Karafin MS, Bruhn R, Westlake M, Sullivan MT, Bialkowski W, Edgren G, Roubinian NH, Hauser RG, Kor DJ, Fleischmann D, Gottschall JL, Murphy EL, Triulzi DJ, National Heart L, Blood Institute Recipient E, Donor Evaluation S, III. Demographic and epidemiologic characterization of transfusion recipients from four US regions: evidence from the REDS-III recipient database. Transfusion. 2017 Dec;57(12):2903-2913. Epub 2017/10/27. doi:10.1111/trf.14370. Cited in: Pubmed; PMID 29067705.

19. Endres-Dighe SM, Guo Y, Kanias T, Lanteri M, Stone M, Spencer B, Cable RG, Kiss JE, Kleinman S, Gladwin MT, Brambilla DJ, D'Andrea P, Triulzi DJ, Mast AE, Page GP, Busch MP, Program NREDES-I. Blood, sweat, and tears: Red Blood Cell-Omics study objectives, design, and recruitment activities. Transfusion. 2019 Jan;59(1):46-56. Epub 2018/09/30. doi:10.1111/trf.14971. Cited in: Pubmed; PMID 30267427.

20. Boknik P, Drzewiecki K, Eskandar J, Gergs U, Hofmann B, Treede H, Grote-Wessels S, Fabritz L, Kirchhof P, Fortmüller L, Müller FU, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J. Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors [Original Research]. Frontiers in Pharmacology. 2019 2019-September-18;Volume 10 - 2019. English. doi:10.3389/fphar.2019.01051.

21. Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, Gauthier C, Jacques P-É, Li S, Xia J. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research. 2021;49(W1):W388-W396. doi:10.1093/nar/gkab382.

22. Moore A, Busch MP, Dziewulska K, Francis RO, Hod EA, Zimring JC, D'Alessandro A, Page GP. Genome-wide metabolite quantitative trait loci analysis (mQTL) in red blood cells from volunteer blood donors. J Biol Chem. 2022 Dec;298(12):102706. eng. Conflict of interest Though unrelated to the contents of this manuscripts, the authors declare that A. D. is a founder of Omix Technologies Inc and Altis Biosciences LLC. A. D. is SAB members for Hemanext Inc. and FORMA Therapeutics Inc. A. D. is a consultant for Rubius Therapeutics. J. C. Z. is a consultant for Rubius Therapeutics and a founder of Svalinn Therapeutics. All other authors have no conflicts of interests to disclose. Epub 20221115. doi:10.1016/j.jbc.2022.102706. Cited in: Pubmed; PMID 36395887.

23. Page GP, Kanias T, Guo YJ, Lanteri MC, Zhang X, Mast AE, Cable RG, Spencer BR, Kiss JE, Fang F, Endres-Dighe SM, Brambilla D, Nouraie M, Gordeuk VR, Kleinman S, Busch MP, Gladwin MT. Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. J Clin Invest. 2021 Jul 1;131(13). eng. Epub 2021/05/21. doi:10.1172/jci146077. Cited in: Pubmed; PMID 34014839.

24. Guo Y, Busch MP, Seielstad M, Endres-Dighe S, Westhoff CM, Keating B, Hoppe C, Bordbar A, Custer B, Butterworth AS, Kanias T, Mast AE, Kleinman S, Lu Y, Page GP. Development and evaluation of a transfusion medicine genome wide genotyping array. Transfusion. 2019 Jan;59(1):101-111. eng. Epub 2018/11/21. doi:10.1111/trf.15012. Cited in: Pubmed; PMID 30456907.

25. Delaneau O, Coulonges C, Zagury J-F. Shape-IT: new rapid and accurate algorithm for haplotype inference. BMC Bioinformatics. 2008 2008/12/16;9(1):540. doi:10.1186/1471-2105-9-540.

26. Howie B, Marchini J, Stephens M. Genotype Imputation with Thousands of Genomes. G3 Genes|Genomes|Genetics. 2011;1(6):457-470. doi:10.1534/g3.111.001198.

27. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics. 2012;28(24):3326-3328. doi:10.1093/bioinformatics/bts606.

28. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics. 2010 2010/03/16;11(1):134. doi:10.1186/1471-2105-11-134.

29. Perry JA, Gaynor BJ, Mitchell BD, O'Connell JR. An Omics Analysis Search and Information System (OASIS) for Enabling Biological Discovery in the Old Order Amish. bioRxiv. 2021:2021.05.02.442370. doi:10.1101/2021.05.02.442370.

**Supplementary Figure 1** –In **A**, paraxanthine levels in 13,091 Index REDS RBC Omics blood units as a function of donor age and sex. In **B**, significant correlation between caffeine and paraxanthine levels. Stratification of paraxanthine (**C**) and paraxanthine/caffeine ratios (**D**) by donor sex, age, BMI, self-reported ethnicity and blood center in which the donors were enrolled.

Supplementary Figure 2 –Metabolite Quantitative Trait Loci (mQTL) analysis for paraxanthine identified a region on chromosome 19 significantly associated with heterogeneity in the level of this metabolite in the 13,091 REDS Index packed RBC units (**A**). Locus Zoom analysis for the total population (**B**) and separate analysis by donor genetic ancestry identified three key single nucleotide polymorphisms (SNPs) in the region coding for CYP2A6, rs7251570, rs76112798 and rs11667314 as the top hits for the total donor populations, or for donors of Asian or European descent, respectively (**C-D**), with rs11667314 and rs721570 likely linked and part of the same haplotype.

Supplementary Figure 3 –Metabolite Quantitative Trait Loci (mQTL) analysis for theobromine identified a region on chromosome 19 significantly associated with heterogeneity in the level of this metabolite in the 13,091 REDS Index packed RBC units (**A**). Locus Zoom analysis for the total population (**B**).

Supplementary Figure 4 –Eight volunteers were randomized to consume a cup of coffee brewed either via Chemex or an espresso, prior to blood collection for plasma and RBC metabolic characterization at baseline, after 45 min or 5h (300 min) after consuming the beverage (**A**). In **B-C**, hierarchical clustering analysis of the top 50 metabolites in RBCs and plasma by linear discriminant analysis as a function of time and brewing method. Metabolites highlighted include caffeine (green), bacterial metabolites (orange), glycolytic metabolites, free fatty acids, acyl-carnitines and lipid oxidation products as a marker of membrane lipid remodeling (dark red). In **D-E**, line plots for RBC caffeine and 2,3-bisphosphoglycerate as a function of time and brewing method.

Supplementary Figure 5 – Delta bilirubin levels (adjusted by donor/recipient weight, sex – y axis) by pre-transfusion bilirubin levels (**A**) or donor age (**B**) as a function of rs785587 SNPs (0 = homozygote dominant; 1 = heterozygote; 2 = homozygote for the alternative or recessive allele – HR).

Supplementary Figure 6 – Stratification of ADORA2b most prevalent SNPs as a function of donor age and BMI in the 13,091 REDS RBC Omics Index cohort (**A**). In **B**, correlates of caffeine levels to metabolites in the 643 REDS RBC Omics Recalled donors (**B**). In **C**, volcano plot of Spearman correlation (x axis) and significance (-log10 of p-values – y axis) of ADORA2b most prevalent SNPs and hemolysis parameters.

Supplementary Figure 7 – Storage of human packed RBCs in presence of adenosine (**A**) did increase intracellular level of this metabolite during the first 2 weeks of storage (**B**), but had minimal effect on the metabolome – which overlapped between controls and supplemented cells (**C**). Changes were noted in glycolysis (lower levels of lactate – line plots in **D**), 2,3-bisphosphoglycerate and ATP or ADP (first week of storage), and AMP, IMP and inosine after storage week 3. Altogether, these results are consistent with adenosine uptake via ENT1, rather than activation of ADORA2b, followed by deamination of adenosine itself or its metabolite AMP into inosine and IMP by adenosine deaminase or RBC-specific AMP deaminase 3 (**E**).

15